- Reference code :
- wf356
- Published date :
-
06 November 2000
- Expired date :
-
24 March 2028
AstraZeneca today announced that it has received approval from the US Food and Drug Administration for 72-hour infusion of Naropin®, a long-acting anaesthetic indicated for the production of local or regional anaesthesia for surgery, postoperative pain management and for obstetrical procedures.
The company received approval for two changes in NaropinÒ labelling: the first allows for dose increase from 5.0 mg/mL to 7.5 mg/mL for Major Nerve Blocks; the second grants approval for an increase in the duration of Naropin infusion from 24 hours to 72 hours for post-operative pain management.
Naropin® is the only long acting anaesthetic with a 72-hour infusion indication.
Other anaesthetic products developed and manufactured by AstraZeneca include Diprivan® Injectable Emulsion, EMLA® , EMLA® Anaesthetic Disc Topical Adhesive System and Xylocaine®.
AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of ethical (prescription) pharmaceuticals and the supply of healthcare services. It is one of the top five pharmaceutical companies in the world with healthcare sales of over $15 billion and leading positions in sales of gastrointestinal, oncology, anaesthesia including pain management, cardiovascular, central nervous system (CNS) and respiratory products.
Further enquires to:
|
Steve Brown +44 (0)20 7304 5033 |
Not signed in
Page tools
Share price
- London
-
26.95 GBP - New York
-
44.82 USD
- Stockholm
-
310.10 SEK
At 21-Nov-2009 06:04 GMT
Detailed share priceIntroduction to AstraZeneca
Our responsibility
We continue to communicate openly on a range of issues, including:
